Recent news highlights focus on Cardinal Health's Q4 2026 earnings, record high stock price post-earnings, strategic outlook for fiscal 2027, and approval of a $5 billion share buyback program.

• Cardinal Health held its Q4 2026 earnings call, discussing fiscal 2027 growth outlook and operational performance [N2].
• The company reported double-digit earnings growth for fiscal 2026 and set a strong outlook for fiscal 2027, with stock price reaching a record high after earnings [N5].
• Cardinal Health approved a $5 billion share repurchase program following Q4 profit increases and growth expectations for fiscal 2027 [N8].
• Analyses highlight Cardinal Health as a strong growth stock with multiple reasons for investor interest based on recent earnings and strategic initiatives [N7].
• The company continues to manage opioid litigation settlements and capital deployment including acquisitions and share repurchases [N2].

Cardinal Health benefits from strong revenue growth driven by branded and specialty pharmaceuticals and strategic acquisitions of MSO platforms, which enhance its service offerings and market penetration. The company's diversified segments and global distribution capabilities provide multiple revenue streams. Recent approvals of substantial share repurchase programs and capital investments in infrastructure and technology support operational efficiency and shareholder returns. Effective management of opioid litigation liabilities and tariff-related cost pressures contributes to financial stability.

Risks include exposure to regulatory and pricing pressures in the pharmaceutical industry, including potential impacts from government policy initiatives on drug pricing. The company faces a dynamic tariff environment that may increase costs in its manufacturing and distribution segments. Goodwill impairments and increased interest expenses from acquisition-related debt highlight financial risks. Ongoing opioid litigation settlements represent significant liabilities with uncertain future payment amounts. Competitive pressures and integration challenges of acquired MSO platforms may affect profitability and growth.

Cardinal Health's moat is supported by its extensive distribution network and scale in pharmaceutical and medical product supply chains, enabling cost efficiencies and broad market reach. Its managed services organization platforms provide integrated support to physician practices, enhancing customer stickiness. The company's diversified product and service offerings across multiple healthcare segments and geographies create barriers to entry. However, exposure to regulatory changes, tariff impacts, and competitive pricing pressures present ongoing challenges to maintaining its competitive position.

• Regulatory and Pricing Pressure: Government policy initiatives and pricing regulations could impact pharmaceutical manufacturer list prices and affect the company's revenue and margins.
• Tariff Environment: Ongoing tariffs on imported products may increase costs in the GMPD and Pharma segments, with incomplete mitigation through pricing or cost optimization.
• Opioid Litigation Liabilities: Significant accrued liabilities related to national opioid litigation settlements require substantial future payments through 2038, posing financial risk.
• Acquisition and Integration Risks: Goodwill impairment charges and increased interest expenses reflect risks associated with acquisitions and integration of MSO platforms.
• Competitive and Market Risks: Competition in healthcare distribution and services, along with reimbursement and regulatory environment changes, may affect market position and profitability.

• Cardinal Health, Inc. is a global healthcare services and products company providing pharmaceuticals, medical products, and services to healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
• The company operates primarily through two reportable segments: Pharmaceutical and Specialty Solutions (Pharma) and Global Medical Products and Distribution (GMPD).
• The Pharma segment distributes branded, generic, and specialty pharmaceuticals, over-the-counter healthcare and consumer products in the U.S., and provides pharmacy management services and managed services organization (MSO) platforms for physician offices.
• The GMPD segment manufactures, sources, and distributes Cardinal Health brand medical, surgical, and laboratory products, as well as national brand products, to healthcare providers in the U.S., Canada, Europe, Asia, and other markets.
• Other operating segments include Nuclear and Precision Health Solutions, at-Home Solutions (including Edgepark and Advanced Diabetes Supply Group), and OptiFreight Logistics.
• Fiscal 2026 revenue was $254.2 billion, a 14% increase from the prior year, driven primarily by branded and specialty pharmaceutical sales growth from existing and new customers.
• GAAP operating earnings for fiscal 2026 increased 15% to $2.6 billion; non-GAAP operating earnings increased 30% to $3.6 billion, reflecting contributions from branded and specialty pharmaceuticals, generics, and acquisitions of MSO platforms and ADS.
• GAAP diluted EPS for fiscal 2026 was $7.23, a 12% increase from the prior year; non-GAAP diluted EPS was $11.26, a 37% increase.
• The company recognized a $184 million pre-tax goodwill impairment charge related to the Navista & Integrated Oncology Network reporting unit within the Pharma segment in fiscal 2026.
• Interest expense increased 62% to $348 million in fiscal 2026, primarily due to additional debt financing for recent acquisitions.
• Effective tax rate was 21.6% in fiscal 2026, impacted by discrete tax items including a $23 million benefit related to the goodwill impairment.
• Cash and cash equivalents were $4.856 billion as of June 30, 2026; current assets were $38.753 billion and current liabilities were $43.904 billion, resulting in a current ratio of 0.88 and a cash ratio of 0.11.
• The company has a $4.0 billion 5-year revolving credit facility expiring in August 2031, replacing prior revolving credit and receivables sale facilities.
• Total long-term obligations including current portion and short-term borrowings were $8.9 billion as of June 30, 2026.
• During fiscal 2026, the company made payments totaling $417 million related to opioid litigation and had $4.3 billion accrued for national opioid litigation settlements, with payments expected through 2038.
• Capital expenditures were $649 million in fiscal 2026, primarily for manufacturing, distribution infrastructure, and technology investments; fiscal 2027 capital expenditures are planned around $700 million.
• The company deployed $1.4 billion for share repurchases in fiscal 2026 and has an approved $5.0 billion share repurchase program as of August 2026.
• The Specialty Alliance MSO platform includes Solaris Health (urology), GI Alliance, Urology America, and other specialty practices; Solaris Health was acquired for approximately $1.9 billion in cash in November 2025.
• The company faces a dynamic tariff environment impacting costs in the GMPD segment and potentially the Pharma segment, with ongoing efforts to mitigate through cost optimization and pricing strategies.
• Recent news highlights include Cardinal Health's Q4 2026 earnings call, record high stock price after earnings, and strategic outlook for fiscal 2027 growth, as well as the approval of a $5 billion buyback program.